medical glp-1 weight loss Amazon launches program Semaglutide GLP-1 for Medical Weight

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

Glucuronidation of Curcuminoids by Human Microsomal and Recombinant UDP-glucuronosyltransferases

Dose escalation phase (titration) Tirzepatide titration (dose escalation) typically follows this schedule: Month 2: 4-6 mg once weekly Month 3: 6-8 mg once weekly Month 4: If tolerated, increase to 8-10 mg once weekly Month 5: If the dosage needs to be escalated further, increase to 10-12 mg once weekly Month 6 and onward: If the dosage needs to be escalated further, increase to 12-14 mg once weekly The maximum dosage is typically 14 mg once weekly if further glycemic control or weight loss is required

tirzepatide 15 mg: -14.7%